Protagenic Therapeutics ( (PTIX) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Protagenic Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The company cites that filing the report by the due date would require unreasonable effort or expense, but assures investors that the report will be filed within the five-day extension period allowed by Rule 12b-25. Protagenic Therapeutics does not anticipate any significant changes in its financial results compared to the previous year, and no forward-looking statements have been made. The company remains committed to compliance, with Chief Financial Officer Alexander K. Arrow signing off on the notification.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Average Trading Volume: 2,667,694
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.7M
Find detailed analytics on PTIX stock on TipRanks’ Stock Analysis page.